Trimunocor is a dynamic spin-out formed to leverage innovations from the Medical Research Council and the University of Southampton focused on finding solutions to combat neonatal chronic lung disease. Our primary innovation centres around the development of natural anti-inflammatory and anti-microbial protein surfactant, protein D for a broad range of anti-inflammatory lung diseases.
To deliver this innovation our team brings together world leading scientific talent, expansive clinical networks and renowned commercial experience together into a team that is poised to deliver exceptional results.
Dr Neill Mackenzie is an internationally networked pharmaceutical executive and serial entrepreneur. Over the last 16 years, Neill has served on the Boards of Trimunocor, Cellualr Therapeutics Ltd, Biotecnol Ltd, CMP Therapeutics Ltd, Roji Ltd Medigene AG, Avidex Ltd, Oxford BioMedica plc and BioMedica Inc and Cambridge Genetics Ltd. As an Executive Director with P&L responsibilities, in listed (both London Stock Exchange and AIM) and private companies he has raised over $150 million equity capital from private and public funds.
Prof Howard Clark BA MA MB BChir MA MD (Cantab) MA DPhil (Oxon) MRCP FRCPCH is Professor and Head of Child Health University of Southampton and Honorary Consultant in Paediatrics (Neonatal Medicine) at the University Hospitals Southampton Trust. He leads the surfactant biology group in the Department of Child Health at Southampton which aims to develop recombinant surfactant proteins A and D as novel therapy for lung inflammation. Prof Clark has over 50 publications on neonatal medicine and surfactant and is President Elect of The Neonatal Society, the foremost internationally recognised neonatal research society. Prof Clark is Co-Founder, with Dr Neill Mackenzie of Trimunocor.
Dr. Alastair Watson Gained his PhD in innate immunology of the lung from the University of Southampton. He developed a novel recombinant immunity protein (recombinant fragment of human surfactant protein A), efficient at preventing respiratory virus infection. Alastair also developed a collaboration in which novel expression systems were introduced to vastly increase the yields of soluble recombinant human surfactant protein D. After training on the ICURe programme and being awarded an Aid for Start-up Innovate grant, Alastair is now project managing the commercialisation of rfhSP-D into a therapeutic for inflammatory lung diseases.